1. Home
  2. MLYS vs WASH Comparison

MLYS vs WASH Comparison

Compare MLYS & WASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • WASH
  • Stock Information
  • Founded
  • MLYS 2019
  • WASH 1800
  • Country
  • MLYS United States
  • WASH United States
  • Employees
  • MLYS N/A
  • WASH N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • WASH Major Banks
  • Sector
  • MLYS Health Care
  • WASH Finance
  • Exchange
  • MLYS Nasdaq
  • WASH Nasdaq
  • Market Cap
  • MLYS 634.6M
  • WASH 613.2M
  • IPO Year
  • MLYS 2023
  • WASH N/A
  • Fundamental
  • Price
  • MLYS $9.77
  • WASH $32.84
  • Analyst Decision
  • MLYS Strong Buy
  • WASH Hold
  • Analyst Count
  • MLYS 2
  • WASH 2
  • Target Price
  • MLYS $30.00
  • WASH $34.00
  • AVG Volume (30 Days)
  • MLYS 266.6K
  • WASH 228.5K
  • Earning Date
  • MLYS 11-11-2024
  • WASH 01-29-2025
  • Dividend Yield
  • MLYS N/A
  • WASH 6.80%
  • EPS Growth
  • MLYS N/A
  • WASH N/A
  • EPS
  • MLYS N/A
  • WASH 2.67
  • Revenue
  • MLYS N/A
  • WASH $188,967,000.00
  • Revenue This Year
  • MLYS N/A
  • WASH N/A
  • Revenue Next Year
  • MLYS N/A
  • WASH $11.60
  • P/E Ratio
  • MLYS N/A
  • WASH $12.30
  • Revenue Growth
  • MLYS N/A
  • WASH N/A
  • 52 Week Low
  • MLYS $8.58
  • WASH $24.11
  • 52 Week High
  • MLYS $16.91
  • WASH $40.59
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 37.52
  • WASH 53.15
  • Support Level
  • MLYS $9.18
  • WASH $28.84
  • Resistance Level
  • MLYS $9.97
  • WASH $33.05
  • Average True Range (ATR)
  • MLYS 0.85
  • WASH 1.01
  • MACD
  • MLYS -0.25
  • WASH 0.44
  • Stochastic Oscillator
  • MLYS 24.53
  • WASH 87.91

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

About WASH Washington Trust Bancorp Inc.

Washington Trust Bancorp Inc through its subsidiaries offers banking and financial services to individuals and businesses. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services including services as trustee, personal representative, custodian and guardian, and settlement of decedents' estates. The bank generates a majority of its revenue from the Commercial Banking segment.

Share on Social Networks: